Skip to main content
Che-Kai Tsao, MD, Oncology, New York, NY

Che-KaiTsaoMDMS

Oncology • New York, NY

Genitourinary Oncology

Medical Director, Ruttenberg Treatment Center and Medical Oncology Prostate Cancer Program, Tisch Cancer Institute, Mount Sinai Hospital

Request Appointment

Overview of Dr. Tsao

Che-Kai Tsao, MD is the Medical Director of the Ruttenberg Treatment Center and the Medical Oncology Prostate Cancer Program at the Tisch Cancer Institute, Mount Sinai Hospital. His mission in this role is to lead this multi-disciplinary treatment center in delivering the highest quality of scientifically innovative and patient centered care to those affected by cancer and blood disorders.

He is an Associate Professor of Medicine, Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai and is on staff at the Tisch Cancer Institute of the Mount Sinai Hospital. He is actively involved in research on the development of novel therapies in the treatment of genitourinary cancers. His main focus is in defining clinical and molecular phenotype of prostate, kidney, and bladder cancers, as well as novel therapies in those disease states.

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2005 - 2008
  • State University of New York Downstate Medical Center College of Medicine
    State University of New York Downstate Medical Center College of MedicineClass of 2005
  • New York University
    New York UniversityB.A., Mathematics and Economics, Cum Laude, 1996 - 2000

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Solid Tumor Faculty Teacher of the Year Tisch Cancer Institute, 2023
  • Fellow Physician of the Year Mount Sinai Hospital, 2012
  • Merit Award American Society of Clinical Oncology, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Activity of Platinum-Based Chemotherapy in Patients with Advanced Prostate Cancer with and Without DNA Repair Gene Aberrations  
    Himisha Beltran, Che-Kai Tsao, Tomasz M Beer, JAMA Network Open
  • Endocrine therapy for prostate cancer: review of the latest clinical evidence  
    Tsao CK, Seng SM, Galsky MD, Oh WK, Clinical Investigation, 4/1/2011
  • Review of cabazitaxel for the treatment of hormone-refractory prostate cancer  
    Tsao CK, Seng SM, Oh WK, Galsky MD, Clinical Medicine Insights: Oncology, 1/1/2011
  • Join now to see all

Press Mentions

  • Study on Veterans Reveals Real-World Survival Outcomes for Targeted Therapies in Advanced Renal Cell Carcinoma
    Study on Veterans Reveals Real-World Survival Outcomes for Targeted Therapies in Advanced Renal Cell CarcinomaNovember 18th, 2019
  • Nivolumab Trial Failure Raises the Question of Brain Imaging in Kidney Cancer
    Nivolumab Trial Failure Raises the Question of Brain Imaging in Kidney CancerJuly 8th, 2019
  • JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCC
    JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCCMarch 6th, 2019

Professional Memberships

Other Languages

  • Chinese (Mandarin), Taiwanese

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Che-Kai Tsao, Dr. Che-Kai Tsao, MD, Dr. C Tsao